GlassScriptPhysician profile
Matthew Hendricks
NPI 1033684873
$11,471.62
in general payments reported to CMS, 2019-2025
31 companies · $3,166 in 2025
The $3,166 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,040 · 2022: $1,524 · 2023: $2,452 · 2024: $3,290 · 2025: $3,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,566 · Education: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,566.36 |
| Education | $341.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,961.23 | 2021-2025 | |
| Genzyme Corporation | $1,419.53 | 2021-2025 | |
| Janssen Biotech, INC. | $1,273.94 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $916.12 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $530.08 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $525.33 | 2023-2025 | Zoryve |
| Ucb, INC. | $521.86 | 2022-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $488.44 | 2022-2025 | Adbry |
| Lilly USA, LLC | $454.61 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $444.66 | 2021-2025 | |
| Galderma Laboratories, L.P. | $423.96 | 2022-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $357.31 | 2022-2024 | Sotyktu |
| Pfizer INC. | $342.39 | 2021-2025 | |
| Dermavant Sciences, INC. | $328.04 | 2023-2024 | Vtama |
| Incyte Corporation | $250.17 | 2021-2025 | Opzelura |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $218.01 | 2024-2025 | Daxxify, Daxi |
| Almirall LLC | $170.67 | 2021-2025 | Seysara |
| Biofrontera INC. | $147.97 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $146.23 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $143.69 | 2021-2023 | Jublia, Duobrii, Arazlo |
| Organogenesis INC. | $119.16 | 2024-2025 | Cygnus Dual, Via Matrix |
| Mayne Pharma Commercial LLC | $82.26 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $50.97 | 2025 | Nuzyra |
| Epi Health, LLC | $35.35 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $24.67 | 2021 | |
| Tempus Ai, INC | $23.67 | 2024 | Merlin Test |
| Fresenius Kabi USA, LLC | $18.69 | 2024 | Idacio |
| Solta Medical, A Division of Bausch Health US, LLC | $18.47 | 2025 | |
| Organon LLC | $14.46 | 2025 | Vtama |
| Dermira, INC. | $13.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $6.30 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.